activins has been researched along with Wasting Disease in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Boor, P; Cohen, CD; Eichinger, F; Hoxha, E; Huber, TB; Kilic, T; Klinkhammer, BM; Kretz, O; Kretzler, M; Kylies, D; Lindenmeyer, MT; Liu, S; Lu, S; Martin, IV; Matsakas, A; Menon, R; Meyer, C; Mitchell, R; Nair, V; Omairi, S; Ostendorf, T; Paolini, A; Pasternack, A; Patel, K; Puelles, VG; Ritvos, O; Sandri, M; Solagna, F; Tezze, C; Tharaux, PL; Turner, JE; Wanner, N; Wiesch, JSZ; Wu, G; Zhao, Y | 1 |
| Brebbia, P; Geisse, S; Glass, DJ; Jacobi, C; Koch, E; Koelbing, C; Lach-Trifilieff, E; Leber, X; Lehmann, S; Minetti, G; Morvan, F; Ritter, V; Rondeau, JM; Scharenberg, M; Scheufler, C; Schilb, A; Toussaint, G; Witte, F; Zou, C | 1 |
| Bertona, M; Emanuele, E; Fiuza-Luces, C; Lucia, A; Morales, JS; Pareja-Galeano, H; Sanchis-Gomar, F | 1 |
| Brown, CA; Chen, L; Matzuk, MM; Wu, X; Yan, C | 1 |
| Graff, JM; Li, Q; Loveland, KL; Matzuk, MM; O'Connor, AE | 1 |
| Kumar, R; Li, Q; Loveland, KL; Matzuk, MM; O'Connor, AE; Seehra, JS; Underwood, K | 1 |
| Boime, I; Byrne, MC; Kumar, TR; Matzuk, MM; Palapattu, G; Wang, P; Woodruff, TK | 1 |
| Chen, L; Cipriano, SC; Kumar, TR; Matzuk, MM | 1 |
| Davies, MV; Esquela, AF; Haynes, P; Koniaris, LG; Lee, SJ; McPherron, AC; Tomkinson, KN; Wolfman, NM; Zimmers, TA | 1 |
9 other study(ies) available for activins and Wasting Disease
| Article | Year |
|---|---|
Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs.
Topics: Activin Receptors, Type II; Activins; Animals; Cachexia; Disease Models, Animal; HEK293 Cells; Humans; Mice; Mice, Knockout; Muscle, Skeletal; Muscular Atrophy; Renal Insufficiency, Chronic; Wasting Syndrome | 2021 |
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Topics: Activin Receptors, Type II; Activins; Animals; Antibodies, Blocking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Morphogenetic Proteins; Crystallography, X-Ray; Dose-Response Relationship, Drug; Growth Differentiation Factors; HEK293 Cells; Humans; Hypertrophy; Male; Mice; Mice, SCID; Muscle, Skeletal; Myostatin; Rats; Rats, Wistar; Recombinant Proteins; Signal Transduction; Wasting Syndrome | 2017 |
Baicalin supplementation reduces serum biomarkers of skeletal muscle wasting and may protect against lean body mass reduction in cancer patients: Results from a pilot open-label study.
Topics: Absorptiometry, Photon; Activins; Aged; Biomarkers; Body Weight; Cachexia; Endpoint Determination; Female; Flavonoids; Humans; Male; Middle Aged; Muscle, Skeletal; Muscular Atrophy; Neoplasms; NF-kappa B; Pilot Projects; Wasting Syndrome; Weight Loss | 2016 |
Interrelationship of growth differentiation factor 9 and inhibin in early folliculogenesis and ovarian tumorigenesis in mice.
Topics: Activins; Animals; Bone Morphogenetic Protein 15; Cachexia; Cell Differentiation; Cell Proliferation; DNA-Binding Proteins; Female; Granulosa Cells; Growth Differentiation Factor 9; Homeodomain Proteins; In Situ Hybridization; Inhibins; Intercellular Signaling Peptides and Proteins; Mice; Mice, Knockout; Mice, Transgenic; Oncogene Proteins; Ovarian Follicle; Ovarian Neoplasms; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Stem Cell Factor; Steroidogenic Factor 1; Theca Cells; Time Factors; Transcription Factors; Up-Regulation; Wasting Syndrome | 2004 |
SMAD3 regulates gonadal tumorigenesis.
Topics: Activins; Animals; Cell Transformation, Neoplastic; Female; Follicle Stimulating Hormone; Inhibins; Male; Mice; Mice, Knockout; Ovarian Neoplasms; RNA, Messenger; Smad3 Protein; Testicular Neoplasms; Wasting Syndrome; Weight Loss | 2007 |
Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
Topics: Activin Receptors, Type II; Activins; Animals; Cachexia; Disease Progression; Female; Follicle Stimulating Hormone; Gastric Mucosa; Immunoglobulin Fc Fragments; Immunoglobulin G; Inhibins; Liver; Male; Mice; Mice, Knockout; Recombinant Fusion Proteins; Sex Cord-Gonadal Stromal Tumors; Stomach; Syndrome; Testicular Neoplasms; Wasting Syndrome | 2007 |
Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis.
Topics: Activins; Animals; Crosses, Genetic; Female; Follicle Stimulating Hormone; Gene Expression Regulation; Hemorrhage; Homozygote; Humans; Infertility, Female; Infertility, Male; Inhibins; Male; Metallothionein; Mice; Mice, Mutant Strains; Mice, Transgenic; Oligopeptides; Ovarian Neoplasms; Ovary; Peptides; Polycystic Ovary Syndrome; Seminal Vesicles; Steroids; Testicular Neoplasms; Urinary Tract; Wasting Syndrome | 1999 |
Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice.
Topics: Activins; Animals; Disease Progression; Female; Follistatin; Glycoproteins; Inhibins; Liver Diseases; Male; Metallothionein; Mice; Mice, Transgenic; Ovarian Neoplasms; Peptides; Stomach Diseases; Survival Analysis; Testicular Neoplasms; Wasting Syndrome | 2000 |
Induction of cachexia in mice by systemically administered myostatin.
Topics: 3T3 Cells; Activins; Adipose Tissue; Animals; Body Weight; Cachexia; CHO Cells; Cricetinae; Eating; Female; Follistatin; Liver; Mice; Mice, Nude; Muscle Fibers, Skeletal; Muscle, Skeletal; Myostatin; Organ Size; Peptide Fragments; Recombinant Proteins; Transforming Growth Factor beta; Wasting Syndrome; Weight Loss | 2002 |